Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $45.14 Consensus PT from Brokerages

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has received an average recommendation of “Buy” from the ten analysts that are currently covering the firm, Marketbeat reports. Eight analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $45.86.

A number of analysts have commented on the company. Raymond James lifted their target price on Dianthus Therapeutics from $51.00 to $56.00 and gave the stock an “outperform” rating in a report on Friday. Wedbush dropped their price target on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a research note on Friday, August 9th. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research note on Thursday, September 26th. Oppenheimer initiated coverage on shares of Dianthus Therapeutics in a report on Thursday, October 3rd. They issued an “outperform” rating and a $48.00 price objective on the stock. Finally, Robert W. Baird began coverage on shares of Dianthus Therapeutics in a research note on Friday, July 26th. They set an “outperform” rating and a $58.00 price target on the stock.

Dianthus Therapeutics Trading Down 2.8 %

DNTH opened at $29.06 on Thursday. The company has a market cap of $853.49 million, a price-to-earnings ratio of -5.25 and a beta of 1.84. Dianthus Therapeutics has a 12-month low of $6.58 and a 12-month high of $33.77. The stock has a fifty day simple moving average of $27.75 and a two-hundred day simple moving average of $26.51.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.15). The company had revenue of $2.17 million for the quarter, compared to the consensus estimate of $1.07 million. Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. On average, analysts predict that Dianthus Therapeutics will post -2.28 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DNTH. Vanguard Group Inc. boosted its holdings in shares of Dianthus Therapeutics by 250.0% during the 1st quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock valued at $16,135,000 after purchasing an additional 384,182 shares during the last quarter. StemPoint Capital LP bought a new position in Dianthus Therapeutics during the first quarter valued at $1,304,000. Bain Capital Life Sciences Investors LLC bought a new stake in shares of Dianthus Therapeutics in the 1st quarter worth about $89,761,000. Janus Henderson Group PLC bought a new position in shares of Dianthus Therapeutics in the 1st quarter valued at about $11,251,000. Finally, RA Capital Management L.P. purchased a new position in Dianthus Therapeutics in the first quarter worth about $69,990,000. 47.53% of the stock is currently owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.